Sumatriptan and Infusion site pruritus - a phase IV clinical study of FDA data

Summary:

Infusion site pruritus is reported as a side effect among people who take Sumatriptan (sumatriptan succinate), especially for people who are female, 50-59 old, also take Epinephrine, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Infusion site pruritus when taking Sumatriptan. It is created by eHealthMe based on reports of 17,179 people who have side effects when taking Sumatriptan from the FDA, and is updated regularly.

What is Sumatriptan?

Sumatriptan has active ingredients of sumatriptan succinate. It is often used in migraine. eHealthMe is studying from 18,159 Sumatriptan users. Check the latest studies of Sumatriptan.

What is Infusion site pruritus?

Infusion site pruritus (severe itching at infusion site) is found to be associated with 473 drugs and 213 conditions by eHealthMe. Check the latest studies of Infusion site pruritus.

On Jul, 18, 2026

17,179 people reported to have side effects when taking Sumatriptan.
Among them, 36 people (0.21%) have Infusion site pruritus.

Could Sumatriptan cause Infusion site pruritus?

Among these 36 people:

What is the gender of people who have Infusion site pruritus when taking Sumatriptan? *

female: 88.89 %
male: 11.11 %

What is the age of people who have Infusion site pruritus when taking Sumatriptan? *

What are other drugs people take besides Sumatriptan? *

What are other side effects people have besides Infusion site pruritus? *

Infusion Site Swelling: 22 people, 61.11%
Sinusitis (inflammation of sinus): 20 people, 55.56%
Infusion Site Pain: 19 people, 52.78%
Infusion Site Erythema (reddening of the skin at infusion site): 15 people, 41.67%
Influenza Like Illness: 13 people, 36.11%
Renal Disorder (kidney disease): 13 people, 36.11%
Urinary Tract Infection: 13 people, 36.11%
Pneumonia: 13 people, 36.11%
Skin Infection: 12 people, 33.33%
Dehydration (dryness resulting from the removal of water): 12 people, 33.33%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 24 people, 66.67%
Primary Immunodeficiency Syndrome: 11 people, 30.56%
Asthma: 7 people, 19.44%
Rhinitis (a medical term for irritation and inflammation of the mucous membrane inside the nose): 2 people, 5.56%
Parkinson's Disease: 2 people, 5.56%
Mycotic Allergy (fungal allergy): 2 people, 5.56%
Multifocal Motor Neuropathy (a progressively worsening condition where muscles in the extremities gradually weaken): 2 people, 5.56%
Immune System Disorder: 2 people, 5.56%
Hypergammaglobulinaemia (elevated levels of gamma globulin): 2 people, 5.56%
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (long lasting infection of nerves outside brain and spinal cord): 2 people, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Sumatriptan and have Infusion site pruritus?

- Check whether Infusion site pruritus is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sumatriptan:

Sumatriptan (18,159 reports)

Browse all side effects of Sumatriptan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infusion site pruritus:

Infusion site pruritus (473 drugs)

Browse all the conditions that are associated with Infusion site pruritus:

Infusion site pruritus (213 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sumatriptan succinate (the active ingredients of Sumatriptan) and Sumatriptan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.